NeuroOne Medical Technologies Corp. Files Updated Prospectus for \$13.4 Million At-the-Market Offering
Eden Prairie, MN, June 12, 2026 – NeuroOne Medical Technologies Corporation (“NeuroOne” or the “Company”, Nasdaq: NMTC), a developer of next-generation surgical and medical instruments, announced a significant update to its capital raising strategy that could impact share value and investor sentiment.
Key Highlights
- Updated Prospectus Filed: On June 12, 2026, NeuroOne filed an updated Prospectus Supplement with the U.S. Securities and Exchange Commission (SEC) for an at-the-market (“ATM”) equity offering program.
- Potential Equity Raise: The updated Prospectus enables the Company to offer and sell up to \$13.4 million of its common stock through JonesTrading Institutional Services LLC acting as its sales agent.
- Legal Opinion Provided: Honigman LLP has issued a legal opinion confirming the validity of the shares to be issued under the ATM program.
- Trading & Listing: The Company’s common stock, with par value \$0.001 per share, continues to trade on Nasdaq under the symbol “NMTC.”
Details of the ATM Program
NeuroOne first entered into the Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC on December 21, 2022. This agreement allows the Company to sell shares from time to time using a method deemed an “at the market offering” as defined by Rule 415(a)(4) under the Securities Act of 1933.
The ATM program provides flexibility to raise capital as needed, without a predetermined schedule, potentially allowing the Company to take advantage of favorable market conditions.
On June 12, 2026, the Company filed an updated Prospectus Supplement, increasing the available amount for issuance to \$13.4 million. Any sales made under the ATM program will be made through JonesTrading as the sales agent, and the shares will be offered pursuant to the Company’s effective Registration Statement and Prospectus.
Implications for Shareholders and Potential Share Price Impact
- Dilution Risk: The issuance of up to \$13.4 million in new shares may result in dilution for existing shareholders, potentially impacting the value of their holdings.
- Capital Infusion: The capital raised will provide NeuroOne with increased financial flexibility to fund its operations, research and development, and potential growth initiatives.
- Market Perception: While ATM programs are common for growth companies, the timing and size of the offering may influence investor sentiment. If the Company issues a large number of shares in a short period, it could put downward pressure on the stock price.
- No Immediate Sale or Offer: The 8-K filing clearly states that this report does not constitute an offer to sell or a solicitation to buy, and no sales will be made in jurisdictions where it would be unlawful.
Regulatory and Legal Notes
- Honigman LLP, as legal counsel, confirmed that the shares issued under the ATM program will be “duly authorized by all necessary corporate action of the Company, and such Shares will be validly issued, fully paid and nonassessable.”
- The legal opinion is limited to matters governed by Delaware General Corporation Law, as NeuroOne is incorporated in Delaware.
Company Information
- Address: 7599 Anagram Dr, Eden Prairie, MN 55344
- Phone: (952) 426-1383
- CEO: David Rosa
- Fiscal Year End: September 30
Important Shareholder Considerations
- Share Dilution: Investors should closely monitor the pace and pricing of share issuance under the ATM program. Unexpected or rapid dilution could negatively affect share prices.
- Future Announcements: The actual use of proceeds and any significant sales activity under this program may be price sensitive and should be watched for future disclosures or press releases.
- No Immediate Financial Statements: This Form 8-K does not contain updated financial statements or earnings information.
Conclusion
The updated ATM program filing is a noteworthy development for NeuroOne Medical Technologies Corporation. It provides the Company with access to up to \$13.4 million in capital, which can be strategically deployed. However, shareholders should be aware of the potential for share dilution and monitor subsequent Company disclosures for the timing and amount of shares sold under the program.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. Investors should conduct their own due diligence and consult with a financial advisor before making investment decisions. The information provided is based on filings made with the SEC and may be subject to change or updates not reflected in this article.
